- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Di | Pharmaceutical Technology Excellence Awards 2025: i3 Membrane | ||
| Di | Overcoming technical challenges in gene therapy product fill-finish operations | ||
| Di | Zambon gains Chinese regulatory authority approval for Fluimucil IV | ||
| Di | Navamedic signs agreement to acquire dne pharma | ||
| Di | Hims & Hers shares plummet 35% as Novo Nordisk pulls partnership plug | ||
| Di | FDA genAI reviews hinge on clarity of dossiers | ||
| Di | FDA approves AstraZeneca and Daiichi Sankyo's Datroway for NSCLC | ||
| Mo | Bayer's Eylea market grip set to slip as Alvotech biosimilar closes in | ||
| Mo | Harbour BioMed partners Otsuka on new T-cell therapy | ||
| Mo | Bridging the gap: A comprehensive approach to social determinants of health | ||
| Mo | EC approves argenx's efgartigimod alfa for CIDP treatment | ||
| Mo | From discovery to delivery: making therapies reach patients faster | ||
| Fr | Madrigal poised to enter European MASH market after CHMP endorsement | ||
| Fr | London Biotechnology Show 2025: Novo Nordisk harnesses AI/ML to accelerate drug development landscape | ||
| Fr | Podcast: Uses of blockchain in healthcare | ||
| Fr | Novartis' ribociclib approved in Canada for early breast cancer | ||
| Fr | FDA cell and gene therapy director exit increases 'volatility' for sector | ||
| Fr | NSW government invests $13.39m in life-changing therapies | ||
| Fr | DoH - Abu Dhabi and Sanofi link for vaccine development | ||
| Do | CNS innovator oligonucleotide licensing value up 339% from £2bn in 2024 | ||
| Do | UK and US governments pursue contrasting vaccine strategies | ||
| Do | Actio gains $66m to advance small molecule therapeutics pipeline | ||
| Do | BioOrbit eyes 2026 for pre-clinical trials of space manufactured protein crystals | ||
| Do | Eli Lilly and Eisai's Alzheimer's drugs denied NHS use due to high costs | ||
| Do | Draig secures $140m for neuropsychiatric disorder therapies |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .